Literature DB >> 26628383

Body Mass Index and Adverse Outcomes in Elderly Patients With Atrial Fibrillation: The AMADEUS Trial.

Keitaro Senoo1, Gregory Y H Lip2.   

Abstract

BACKGROUND AND
PURPOSE: Obesity has been associated with increased cardiovascular risk in atrial fibrillation, but little is known in elderly patients with atrial fibrillation.
METHODS: Post hoc analysis of data from the AMADEUS (Evaluating the Use of SR34006 Compared to Warfarin or Acenocoumarol in Patients With Atrial Fibrillation) trial.
RESULTS: We studied 1588 elderly patients, who were categorized as normal body mass index (BMI, 18.5-25 kg/m(2); n=515 [32.4%]), overweight (BMI, 25-30 kg/m(2); n=711 [44.8%]), and obese (BMI≥30 kg/m(2); n=362 [22.8%]). There was a significant reduction in the composite outcome of cardiovascular death and stroke/systemic embolism with increasing BMI category, being 5.0%, 3.2%, and 1.5% per 100 patient-years, respectively (P for trend=0.01). Cox proportional hazards analysis found obesity to be associated with a lower risk of the primary composite outcome (hazard ratio, 0.29; 95% confidence interval, 0.11-0.77; P=0.01). In the warfarin arm (n=814), multivariate logistic regression analysis demonstrated that obesity was independently related to higher odds of time in therapeutic range ≥60% (odds ratio, 1.84; 95% confidence interval, 1.21-2.80; P=0.004).
CONCLUSION: Obesity was associated with a lower stroke and mortality rate in elderly anticoagulated atrial fibrillation patients. Obesity was related to good quality anticoagulation control.
© 2015 American Heart Association, Inc.

Entities:  

Keywords:  atrial fibrillation; international normalized ratio; mortality; obesity; stroke

Mesh:

Substances:

Year:  2015        PMID: 26628383     DOI: 10.1161/STROKEAHA.115.011876

Source DB:  PubMed          Journal:  Stroke        ISSN: 0039-2499            Impact factor:   7.914


  10 in total

1.  Impact of Age on the Association Between Body Mass Index and All-Cause Mortality in Patients with Atrial Fibrillation.

Authors:  S Wu; Y M Yang; J Zhu; H B Wan; J Wang; H Zhang; X H Shao
Journal:  J Nutr Health Aging       Date:  2017       Impact factor: 4.075

2.  Reply to 'Body mass index and the risk of all-cause mortality among patients with nonvalvular atrial fibrillation: a multicenter prospective observational study in China; methodological issues'.

Authors:  S Wu; H Wan; J Wang; Y Yang; J Zhu; X Shao; B Huang; H Zhang
Journal:  Eur J Clin Nutr       Date:  2017-05-03       Impact factor: 4.016

3.  Obesity Paradox in Ischemic Stroke: Clinical and Molecular Insights.

Authors:  Emilio Rodríguez-Castro; Manuel Rodríguez-Yáñez; Susana Arias-Rivas; María Santamaría-Cadavid; Iria López-Dequidt; Pablo Hervella; Miguel López; Francisco Campos; Tomás Sobrino; José Castillo
Journal:  Transl Stroke Res       Date:  2019-04-13       Impact factor: 6.829

4.  A retrospective study on the risk factors for bleeding events in warfarin therapy, focusing on renal function.

Authors:  Toshinori Hirai; Yukihiro Hamada; Yujiro Geka; Shiori Kuwana; Koji Hirai; Mai Ishibashi; Yutaka Fukaya; Toshimi Kimura
Journal:  Eur J Clin Pharmacol       Date:  2017-08-09       Impact factor: 2.953

5.  Body mass index and all-cause mortality in patients with atrial fibrillation: insights from the China atrial fibrillation registry study.

Authors:  Lu Wang; Xin Du; Jian-Zeng Dong; Wen-Na Liu; Ying-Chun Zhou; Song-Nan Li; Xue-Yuan Guo; Chen-Xi Jiang; Rong-Hui Yu; Cai-Hua Sang; Ri-Bo Tang; De-Yong Long; Nian Liu; Rong Bai; Laurent Macle; Chang-Sheng Ma
Journal:  Clin Res Cardiol       Date:  2019-04-05       Impact factor: 5.460

Review 6.  Thrombosis in the setting of obesity or inflammatory bowel disease.

Authors:  Steven R Lentz
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2016-12-02

Review 7.  The impact of underweight and obesity on outcomes in anticoagulated patients with atrial fibrillation: A systematic review and meta-analysis on the obesity paradox.

Authors:  Maxim Grymonprez; Andreas Capiau; Tine L De Backer; Stephane Steurbaut; Koen Boussery; Lies Lahousse
Journal:  Clin Cardiol       Date:  2021-03-26       Impact factor: 2.882

Review 8.  Relation of Body Mass Index With Adverse Outcomes Among Patients With Atrial Fibrillation: A Meta-Analysis and Systematic Review.

Authors:  Wengen Zhu; Rong Wan; Fuwei Liu; Jinzhu Hu; Lin Huang; Juxiang Li; Kui Hong
Journal:  J Am Heart Assoc       Date:  2016-09-09       Impact factor: 5.501

9.  Low Performance of a Clinical-Genetic Model in the Estimation of Time in Therapeutic Range in Acenocoumarol-Adherent Patients with Nonvalvular Atrial Fibrillation: The Quality of Anticoagulation Challenge.

Authors:  Samantha Wasniewski; Luciano Consuegra-Sánchez; Pablo Conesa-Zamora; Luis García de Guadiana-Romualdo; Pablo Ramos-Ruiz; Marta Merelo-Nicolás; F Guillermo Clavel-Ruipérez; Begoña Alburquerque-González; Federico Soria-Arcos; Juan A Castillo-Moreno
Journal:  Biomed Res Int       Date:  2018-10-17       Impact factor: 3.411

10.  Obesity paradox on outcome in atrial fibrillation maintained even considering the prognostic influence of biomarkers: insights from the ARISTOTLE trial.

Authors:  Roopinder K Sandhu; Justin A Ezekowitz; Ziad Hijazi; Johan Westerbergh; Julia Aulin; John H Alexander; Christopher B Granger; Sigrun Halvorsen; Michael S Hanna; Renato D Lopes; Agneta Siegbahn; Lars Wallentin
Journal:  Open Heart       Date:  2018-11-01
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.